Oxbryta Tablet, Film Coated
Product Images NDC 72786-102

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Oxbryta (NDC 72786-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Global Blood Therapeutics, Inc, A Subsidiary Of Pfizer Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oxbryta 01)

Chemical structure diagram of voxelotor, the active ingredient in OXBRYTA tablets. The structure displays the molecular arrangement of atoms and bonds characteristic of voxelotor.*

FDA Label Image

Figure 1 (Oxbryta 02)

A vertical bar chart comparing the change from baseline in hemoglobin concentration (g/dL) at 24 weeks between two groups: Voxelotor 1500 mg (n=75) and placebo (n=77). The chart shows individual patient changes, with mostly positive changes in the Voxelotor group and a wider range including negative changes in the placebo group.*

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Label)

An instructional illustration showing a bottle labeled 'a clear drink,' a glass, and a medicine measuring spoon marked with '1 tsp,' indicating the amount of medication to be taken with a clear liquid.*

FDA Label Image

Oxbryta 04

An instructional illustration showing a liquid being poured from a spoon into a measuring cup, likely depicting a dose measurement step for an oral medication.*

FDA Label Image

Oxbryta 05

An illustration showing a hand holding a round tablet labeled "300 mg" above a glass of water, demonstrating the act of swallowing the tablet.*

FDA Label Image

Oxbryta 06

An instructional illustration showing a hand rotating a clear cup containing a liquid. The image indicates a swirling or mixing action with a red arrow inside the cup, suggesting the liquid should be stirred or swirled before use.*

FDA Label Image

Oxbryta 07

An instructional illustration showing a stopwatch indicating a time range of 1 to 5 minutes next to a transparent container partially filled with liquid, suggesting a mixing or timing step related to medication preparation or administration.*

FDA Label Image

Oxbryta 08

An instructional illustration showing a person drinking a glass of liquid, depicting the oral administration route for a medication.*

FDA Label Image

Oxbryta 09

An illustration showing a bottle, a measuring cup, and a spoon with liquid dripping from the spoon into the cup. The image likely represents medication measurement or administration instructions.*

FDA Label Image

Oxbryta 10

Label for Oxbryta (voxelotor) 500 mg film-coated tablets, oral use, by Global Blood Therapeutics, Inc., a Pfizer subsidiary. Packaging specifies 90 tablets per container, storage instructions, and warnings about safety seal and tablet handling.*

FDA Label Image

Oxbryta 11

OXBRYTA 300 mg film-coated tablets packaging label for oral suspension, containing 90 tablets. The label specifies voxelotor as the active ingredient and instructions that tablets must be dispersed in water or clear liquid prior to ingestion and not chewed or swallowed whole. Manufactured by Global Blood Therapeutics, Inc, a Pfizer subsidiary.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.